Aardvark Therapeutics (AARD) Capital Expenditures (2024 - 2025)
Aardvark Therapeutics (AARD) reported Capital Expenditures of $4000.0 for Q3 2025, down 20.0% on a YoY basis from $5000.0 in Q3 2024, and down 95.6% sequentially from $91000.0 in Q2 2025.
Aardvark Therapeutics (AARD) Capital Expenditures (2024 - 2025) Analysis & Trends
Aardvark Therapeutics (AARD) has 2 years of Capital Expenditures data on file, last reported at $4000.0 in Q3 2025.
- For the quarter ending Q3 2025, Capital Expenditures fell 20.0% year-over-year to $4000.0; the trailing twelve-month figure through Dec 2025 stood at $95000.0 (down 12.84% YoY), and the FY2025 full-year result was $95000.0, down 12.84% from the prior year.
- Capital Expenditures fell to $4000.0 in Q3 2025, from $91000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $93000.0 in Q2 2024 to a low of $4000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Aardvark Therapeutics | 139.40 Mn | 19.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 4,000.00 |
| Sep 30, 2025 | 4,000.00 |
| Jun 30, 2025 | 91,000.00 |
| Jun 30, 2025 | 91,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 93,000.00 |
| Jun 30, 2024 | 93,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Mar 31, 2024 | 5,000.00 |